Evidence map›Paper›PMID 29496260›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018

Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Richard J Johnson, George L Bakris, Claudio Borghi, Michel B Chonchol, David Feldman, Miguel A Lanaspa, Tony R Merriman, Orson W Moe, David B Mount, Laura Gabriella Sanchez Lozada and 3 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 332 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
332citing papers in PubMed, 2 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

332 citing papers in PubMed, 2 syntheses or guidelines pooled it, 628 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effects of Sacubitril/Allisartan versus Olmesartan on serum uric acid in Chinese patients with hypertension and hyperuricaemia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

272 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 4 countries.

Richard J JohnsonUniversity of Colorado, Denver, CO.
George L BakrisUniversity of Chicago Medicine, Chicago, IL.
Claudio BorghiUniversity of Bologna, Bologna, Italy.
Michel B ChoncholUniversity of Colorado, Denver, CO.
David FeldmanNational Kidney Foundation, New York City, NY.
Miguel A LanaspaUniversity of Colorado, Denver, CO.
Tony R MerrimanUniversity of Otago, Dunedin, NZ.
Orson W MoeUniversity of Texas Southwestern Medical Center, Dallas, TX.
David B MountBrigham and Women's Hospital, Harvard Medical School, Boston, MA.
Laura Gabriella Sanchez LozadaInstituto Nacional de Cardiología, Ignacio Chávez, Mexico City, Mexico.
Eli StahlMount Sinai School of Medicine, New York City, NY.
Daniel E WeinerTufts Medical Center, Boston, MA.
Glenn M ChertowStanford University, Stanford, CA. Electronic address: gchertow@stanford.edu.
University of Colorado Denver · USHarvard University · USIcahn School of Medicine at Mount Sinai · USInstituto Nacional de Cardiología · MXNational Kidney Foundation · USStanford University · USThe University of Texas Southwestern Medical Center · USTufts Medical Center · USUniversity of Bologna · ITUniversity of Chicago · USUniversity of Otago · NZ

Funding

Klotho and Phosphate in Chronic Kidney Disease: Pathogenesis and TherapeuticsR01DK091392 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HU, MING-CHANG, MOE, ORSON W · 2011 to 2021
$3.2M
NIDDK NIH HHS R01 DK091392
6 · The paper itself

Abstract

Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, cardiovascular disease, and diabetes remains controversial. A scientific workshop organized by the National Kidney Foundation was held in September 2016 to review current evidence. Cell culture studies and animal models suggest that elevated serum urate concentrations can contribute to kidney disease, hypertension, and metabolic syndrome. Epidemiologic evidence also supports elevated serum urate concentrations as a risk factor for the development of kidney disease, hypertension, and diabetes, but differences in methodologies and inpacts on serum urate concentrations by even subtle changes in kidney function render conclusions uncertain. Mendelian randomization studies generally do not support a causal role of serum urate in kidney disease, hypertension, or diabetes, although interpretation is complicated by nonhomogeneous populations, a failure to consider environmental interactions, and a lack of understanding of how the genetic polymorphisms affect biological mechanisms related to urate. Although several small clinical trials suggest benefits of urate-lowering therapies on kidney function, blood pressure, and insulin resistance, others have been negative, with many trials having design limitations and insufficient power. Thus, whether uric acid has a causal role in kidney and cardiovascular diseases requires further study.

Indexed as

Acute Kidney InjuryAge FactorsCardiovascular DiseasesComorbidityEducationFemaleHumansHypertensionHyperuricemiaMalePrevalencePrognosisRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSex Factorscardiovascular disease (CVD)chronic kidney disease (CKD)diabetesgouthypertensionhyperuricemiakidney functionreviewserum urateUric acidxanthine oxidoreductase

Identifiers

PMID29496260
PMCPMC7286363
OpenAlexW2789006309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.